Acquisition lifts revenue 94% but PBT halves and dividend is cut 36%

What changed

FY23 revenue rose 94.4% to NZ$11.467m, but this is not a like-for-like outcome — the prior period predates the recent General Practice acquisitions, so the comparison embeds an inorganic step-up rather than organic growth. Profit before tax fell 53.4% to NZ$0.727m and reported NPAT fell 62.7% to NZ$0.438m; PBT is the cleaner read because the effective tax rate swung adversely (the calculation pass flags tax distortion). Operating cash flow was essentially flat at NZ$1.081m versus NZ$1.063m. The balance sheet expanded materially: total assets doubled to NZ$10.044m, total liabilities tripled to NZ$7.500m, gross borrowings of NZ$2.341m appeared (none disclosed prior), and equity eased to NZ$2.544m. The final dividend was cut to 2.577cps from 4.050cps (–36.4%).

What matters

• Earnings quality went backwards while revenue scaled. Doubling the top line produced lower PBT and lower NPAT; the segment split shows aged care medical services delivered NZ$0.709m of segment PBT versus just NZ$0.018m from general practice — i.e., almost all profit still comes from the legacy aged care book, not the acquired GP footprint that drove the revenue jump.
• Balance sheet has been re-geared. Gross borrowings of NZ$2.341m are new, net debt is around NZ$0.986m (≈0.6x EBITDA), and equity has slipped despite the asset doubling. ROE dropped from 43.5% to 17.2%.
• The dividend cut is the clearest management signal. Even with the 36.4% reduction, payout-to-NPAT rose to 62.7% from 34.0%, indicating the prior payout shape is no longer supportable at current earnings.

Expectations

No quantitative target or guidance is provided. The only forward shape disclosure is a ~NZ$150k p.a. cost-out flagged at the half. Half-year context is available and is unflattering: HY23 carried NZ$0.324m of NPAT, implying a 2H NPAT of only NZ$0.114m — i.e., earnings decelerated into year-end despite management framing the second half as outpacing the first. Revenue and EBITDA were more evenly distributed (1H share 39.9% and 44.6% respectively), so the 2H NPAT softness is a margin/cost story, not a revenue one. The release does not support a clean inflection narrative; it does support the claim that revenue scale has been delivered.

Quality of result

Mixed quality. Operating cash flow conversion looks reasonable on the EBITDA base (OCF/EBITDA ~69%), and pre-lease FCF of NZ$1.029m is broadly in line with prior. However, trade receivables jumped from NZ$0.386m to NZ$1.117m, lifting receivable days from 23.9 to 35.5 — a working-capital headwind that is currently being absorbed but warrants monitoring as the GP book annualises. EBITDA of NZ$1.557m is disclosed without a bridge to PBT, and no prior-year EBITDA is provided, so the headline "EBITDA" cannot be assessed on a like-for-like basis. The healthcare-specific caution applies: with the operating model still being bedded in across acquired practices, current margins should not be assumed to be a steady-state level.

Unresolved

• What is the organic versus acquired split of FY23 revenue, and how is the GP book trading on a same-practice basis?
• Why did the effective tax rate increase so sharply, and is the FY23 charge structural or one-off?
• What are the repayment terms and covenants on the NZ$2.341m bank debt, and how does that constrain dividend capacity from here?
• Is the receivables build (35.5 days) an integration artefact or a structural feature of the acquired contract mix?
• Will the flagged NZ$150k p.a. cost-out fully recover the 2H margin compression, or is more re-basing required?

This briefing cannot assess valuation, share-price reaction, or the standalone profitability of the acquired GP practices, because NTA, market data, and acquired-entity revenue/cost detail were not in the supplied materials.

Key metrics

Segment breakdown

Analytical metrics

This analysis was generated using Annolyse, an AI-powered tool that analyses NZX company announcements. The analysis is based on available company filings and standard Annolyse calculations. This is general information only and does not constitute financial advice. The analysis may contain errors. Always read the original company filings and consult a licensed financial adviser before making investment decisions.